Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report released on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock.

Other analysts have also issued research reports about the company. Piper Sandler assumed coverage on Aquestive Therapeutics in a research note on Thursday, April 11th. They issued an overweight rating and a $10.00 price objective on the stock. Raymond James initiated coverage on Aquestive Therapeutics in a research report on Thursday, March 28th. They set an outperform rating and a $7.00 price target on the stock. Finally, JMP Securities raised their target price on Aquestive Therapeutics from $8.00 to $10.00 and gave the company an outperform rating in a report on Friday, March 15th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Aquestive Therapeutics has an average rating of Buy and a consensus target price of $8.00.

Aquestive Therapeutics Stock Up 7.3 %

Shares of Aquestive Therapeutics stock opened at $3.52 on Tuesday. Aquestive Therapeutics has a 12 month low of $1.25 and a 12 month high of $6.23. The stock has a market cap of $320.46 million, a PE ratio of -25.14 and a beta of 2.95. The business has a fifty day simple moving average of $4.25 and a 200 day simple moving average of $2.87.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The firm had revenue of $13.21 million during the quarter, compared to the consensus estimate of $11.79 million. Analysts expect that Aquestive Therapeutics will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Alexander Mark Schobel sold 25,000 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $5.19, for a total transaction of $129,750.00. Following the completion of the transaction, the insider now directly owns 1,040,371 shares of the company’s stock, valued at approximately $5,399,525.49. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AQST. Armistice Capital LLC grew its stake in shares of Aquestive Therapeutics by 314.5% in the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after buying an additional 3,642,000 shares during the period. Essex Investment Management Co. LLC bought a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $1,709,000. Acadian Asset Management LLC raised its holdings in shares of Aquestive Therapeutics by 238.8% in the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock worth $841,000 after purchasing an additional 388,017 shares during the period. Janney Montgomery Scott LLC bought a new stake in Aquestive Therapeutics during the 1st quarter valued at $1,456,000. Finally, Legato Capital Management LLC bought a new stake in Aquestive Therapeutics during the 4th quarter valued at $688,000. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.